Literature DB >> 21722313

PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.

Elena Cubedo1, Michelle Maurin, Xiaoyu Jiang, Izidore S Lossos, Kenneth L Wright.   

Abstract

Human germinal center-associated lymphoma (HGAL) and LIM domain only-2 (LMO2) are proteins highly expressed in germinal center (GC) B lymphocytes. HGAL and LMO2 are also expressed in GC-derived lymphomas and distinguish biologically distinct subgroups of diffuse large B-cell lymphomas (DLBCL) associated with improved survival. However, little is known about their regulation. PRDM1/Blimp1 is a master regulator of terminal B cell differentiation and may also function as a tumor suppressor in the pathogenesis of DLBCL, where it is frequently inactivated by mutations and deletions. We now demonstrate that both HGAL and LMO2 are directly regulated by the transcription repressor PRDM1. In vivo studies demonstrate that PRDM1 directly binds to the recognition sites within the upstream promoters of both HGAL and LMO2. PRDM1 binding suppresses endogenous protein and mRNA levels of HGAL and LMO2. In addition, promoter analysis reveals that site-specific binding of PRDM1 to the promoters is capable of repressing transcriptional activity. This inhibitory effect of PRDM1 suggests that it has a key role in the loss of HGAL and LMO2 expression upon differentiation of GC B cells to plasma cells and may also contribute to absence of HGAL and LMO2 expression in post-GC lymphoid tumors.
© 2011 The Authors Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722313      PMCID: PMC3158840          DOI: 10.1111/j.1742-4658.2011.08227.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  56 in total

1.  A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene.

Authors:  Scott C Crable; Kathleen P Anderson
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

2.  Transcriptional analysis of the B cell germinal center reaction.

Authors:  Ulf Klein; Yuhai Tu; Gustavo A Stolovitzky; Jeffrey L Keller; Joseph Haddad; Vladan Miljkovic; Giorgio Cattoretti; Andrea Califano; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

3.  Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells.

Authors:  N Ghosh; I Gyory; G Wright; J Wood; K L Wright
Journal:  J Biol Chem       Date:  2001-01-30       Impact factor: 5.157

4.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program.

Authors:  A L Shaffer; Kuo I Lin; Tracy C Kuo; Xin Yu; Elaine M Hurt; Andreas Rosenwald; Jena M Giltnane; Liming Yang; Hong Zhao; Kathryn Calame; Louis M Staudt
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

5.  BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells.

Authors:  J F Piskurich; K I Lin; Y Lin; Y Wang; J P Ting; K Calame
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

6.  The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.

Authors:  Y Yamada; R Pannell; A Forster; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

8.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells.

Authors:  Miriam Shapiro-Shelef; Kuo-I Lin; Louise J McHeyzer-Williams; Jerry Liao; Michael G McHeyzer-Williams; Kathryn Calame
Journal:  Immunity       Date:  2003-10       Impact factor: 31.745

9.  Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells.

Authors:  Kuo-I Lin; Cristina Angelin-Duclos; Tracy C Kuo; Kathryn Calame
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

10.  HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

Authors:  Izidore S Lossos; Ash A Alizadeh; Ranjani Rajapaksa; Robert Tibshirani; Ronald Levy
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

View more
  4 in total

1.  miR-155 regulates HGAL expression and increases lymphoma cell motility.

Authors:  Liat Nadav Dagan; Xiaoyu Jiang; Shruti Bhatt; Elena Cubedo; Klaus Rajewsky; Izidore S Lossos
Journal:  Blood       Date:  2011-11-16       Impact factor: 22.113

2.  Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.

Authors:  Lou-Ella M M Alexander; January Watters; Jessica A Reusch; Michelle Maurin; Brook S Nepon-Sixt; Katerina Vrzalikova; Mark G Alexandrow; Paul G Murray; Kenneth L Wright
Journal:  Mol Immunol       Date:  2017-08-31       Impact factor: 4.407

3.  FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.

Authors:  Kah Keng Wong; Duncan M Gascoyne; Elizabeth J Soilleux; Linden Lyne; Hayley Spearman; Giovanna Roncador; Lars M Pedersen; Michael B Møller; Tina M Green; Alison H Banham
Journal:  Oncotarget       Date:  2016-08-16

4.  EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.

Authors:  Christine T Styles; Quentin Bazot; Gillian A Parker; Robert E White; Kostas Paschos; Martin J Allday
Journal:  PLoS Biol       Date:  2017-08-03       Impact factor: 8.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.